期刊文献+

人DR5胞外区域克隆及在大肠埃希菌中表达 被引量:1

Cloning and expression of extracellular fragment of human DR5 in E.coli
下载PDF
导出
摘要 目的克隆人死亡受体5(DR5)cDNA的胞外区域(eDR5),构建原核重组表达载体pGEX-eDR5,使eDR5在大肠埃希菌中表达。方法采用RT-PCR(反转录PCR)方法从人肝癌细胞HepG2中获得eDR5,然后克隆到pMD19-T载体上进行测序,得到正确的基因片段。经双酶切将目的基因片段插入到原核表达载体pGEX-4T-1上,测序正确后,转入大肠埃希菌BL21(DE3)中用IPTG诱导表达GST-eDR5融合蛋白,最后用十二烷基磺酸钠聚丙烯酰胺凝胶电泳(SDS-PAGE)检测目的蛋白的表达量。结果重组克隆载体pMD-eDR5经测序鉴定序列正确。构建的融合表达载体pGEX-eDR5在大肠埃希菌中表达,可溶性目的蛋白占细菌总蛋白约19%。结论成功克隆了人DR5 cDNA的胞外区域,并在大肠埃希菌中表达。为下一步分离纯化人DR5重组蛋白,制作多克隆抗体提供基础依据。 Objective To clone the extracellular fragment of human DR5 (death receptor 5 )cDNA(eDR5) and express it in E. coli cells. Methods The eDR 5 was amplified from human liver cancer cell line HepG2 by RT- PCR (reverse tran- scription PCR), and was cloned into the vector pMD19- T. After verified by sequencing, it was cut with restriction endonu- cleases BarnH I and EcoR I, and then the eDR5 was extracted and inserted into the prokaryotic expression vector pGEX - 4T - 1 and verified by sequencing. Finally the recombinant expression plasmid pGEX - eDR5 was transformed into E. coli BL21 (DE3), and induced to express the GST - eDR5 fusion protein with IPTG. Expressed protein was identified by SDS - PAGE. Results Sequence analysis proved that the eDR5 was correct and prokaryotic expression plasmid pGEX - eDR5 was constructed successfully. The GST - eDR5 fusion protein was expressed in E. coli BL21 (DE3) at a high level which accounted for about 19% of the total bacterial cellular proteins. Conclusion The extraceUular fragment of human DR5 cDNA was cloned successfully and was expressed at a high level in E. coli. This research laid a foundation for purifying human DR5 polypeptides and generating anti - human DR5 polyclonal antibody.
出处 《中国公共卫生》 CAS CSCD 北大核心 2008年第6期762-764,共3页 Chinese Journal of Public Health
基金 内蒙古自然科学基金项目(200408020909)
关键词 死亡受体5 基因克隆 原核表达 death receptor 5 (DRS) gene cloning prokaryotic expression
  • 相关文献

参考文献1

二级参考文献131

  • 1[1]Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271:12687-90.
  • 2[2]Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-82.
  • 3[3]Wajant H, Moosmayer D, Wuest T, et al. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001; 20:4101-6.
  • 4[4]Tecchio C, Huber V, Scapini P, et al. IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 2004;103:3837-44
  • 5[5]Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276:111-3.
  • 6[6]Walczak H, Degli-Esposti MA, Johnson RS, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. Embo J 1997;16:5386-97.
  • 7[7]MacFarlane M, Ahmad M, Srinivasula SM, et al. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997; 272:25417-20.
  • 8[8]Screaton GR, Mongkolsapaya J, Xu XN, et al. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997; 7:693-6.
  • 9[9]Degli-Esposti MA, Dougall WC, Smolak PJ, et al. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7:813-20.
  • 10[10]Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186:1165-70.

共引文献26

同被引文献9

  • 1Hatch M, Cornelius J, Allison M, et al. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int, 2006, 69(4): 691-698.
  • 2Mittal RD, Kumar R. Gut-inhabiting bacterium Oxalobacter formigenes: role in calcium oxalate urolithiasis. J Endourol, 2004, 18(5): 418-424.
  • 3Hoppe B, Beck B, Garter N, et al. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int, 2006, 70(7): 1195-1200.
  • 4Sidhu H, Ogden SD, Lung HY, et al. DNA Sequencing and Expression of the Formyl Coenzyme A Transferase Gene, frc, from Oxalobacter formigenes. J Bacteriol, 1997, 179(10): 3378-3381.
  • 5Corbetta S, Baccarelli A, Aroldi A, et al. Risk factors associated to kidney stones in primary hyperparathyroidism. J Endocrinol Invest, 2005, 28(2): 122-128.
  • 6Hatch M, Freel RW, Vaziri ND. Characteristics of the transport of oxalate and other ions across rabbit proximal colon. Pflugers Arch 1993, 423(3-4): 206-212.
  • 7Azcarate-Peril MA, Bruno-Barcena JM, Hassan HM, et al. Transcriptional and functional analysis of oxalyl-coenzyme A (CoA) decarboxylase and formyl-CoA transferase genes from Lactobacillus acidophilus. Appl Environ Microbial, 2006, 72(3): 1891-1899.
  • 8Federici F, Vitali B, Gotti R, et al. Characterization and heterologous expression of the oxalyl eoenzyme A deearboxylase gene from Bifidobacterium laetis. Appl Environ Mierobiol, 2004, 70 (9): 5066- 5073.
  • 9罗耀玲,王勇,黄雪萍,冉丹霞,马永平,宋方洲.大肠埃希菌热不稳定肠毒素B亚单位在婴儿双歧杆菌中的表达[J].中国微生态学杂志,2008,20(2):113-115. 被引量:12

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部